Mutual of America Capital Management LLC Sells 3,144 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Mutual of America Capital Management LLC lowered its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 0.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 397,772 shares of the medical equipment provider’s stock after selling 3,144 shares during the period. Mutual of America Capital Management LLC owned 0.86% of BioLife Solutions worth $9,960,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. 1620 Investment Advisors Inc. bought a new position in shares of BioLife Solutions during the second quarter valued at $35,000. GAMMA Investing LLC increased its stake in BioLife Solutions by 29.4% during the 3rd quarter. GAMMA Investing LLC now owns 3,295 shares of the medical equipment provider’s stock valued at $83,000 after purchasing an additional 748 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in BioLife Solutions in the second quarter worth about $122,000. Summit Global Investments bought a new position in shares of BioLife Solutions in the third quarter worth approximately $228,000. Finally, Arizona State Retirement System bought a new position in shares of BioLife Solutions in the second quarter worth approximately $217,000. Hedge funds and other institutional investors own 93.24% of the company’s stock.

Analysts Set New Price Targets

BLFS has been the subject of a number of recent analyst reports. Craig Hallum boosted their price objective on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. HC Wainwright started coverage on BioLife Solutions in a report on Monday, September 30th. They set a “buy” rating and a $29.00 price target on the stock. Northland Securities lifted their price objective on BioLife Solutions from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Finally, TD Cowen upped their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $27.83.

BioLife Solutions Stock Performance

Shares of BLFS opened at $21.02 on Monday. The firm has a market capitalization of $975.12 million, a P/E ratio of -19.83 and a beta of 1.88. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.81. BioLife Solutions, Inc. has a one year low of $11.40 and a one year high of $28.88. The business has a fifty day moving average of $24.00 and a 200 day moving average of $22.82.

Insiders Place Their Bets

In related news, CRO Garrie Richardson sold 3,070 shares of BioLife Solutions stock in a transaction on Monday, September 16th. The stock was sold at an average price of $25.12, for a total transaction of $77,118.40. Following the transaction, the executive now directly owns 114,773 shares in the company, valued at approximately $2,883,097.76. The trade was a 2.61 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Aby J. Mathew sold 10,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $23.28, for a total value of $232,800.00. Following the completion of the sale, the executive vice president now owns 317,716 shares of the company’s stock, valued at approximately $7,396,428.48. The trade was a 3.05 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 27,471 shares of company stock valued at $656,330. Insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.